Now is the time for regenerative medicine clinics, related medical service providers, and industry to comply with current regulations concerning Human Cells, Tissues and Cellular and Tissue-based Products (HCT/Ps). 

​

Across the United States, targeted enforcement of federal regulatory standards for the field of regenerative medicine has intensified. 

​

The US FDA, state authorities, professional licensing bodies, and other oversight agencies are all involved. Tech giants are now using their powerful search algorithms to identify  language used to promote the  stem cell  industry, and they too have tightened their own rules relating to the marketing tools used by those who practice regenerative medicine.